See more : Navios Maritime Holdings Inc. (NM) Income Statement Analysis – Financial Results
Complete financial analysis of Morepen Laboratories Limited (MOREPENLAB.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Morepen Laboratories Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Sparta Capital Ltd. (SCAXF) Income Statement Analysis – Financial Results
- Onewo Inc. (2602.HK) Income Statement Analysis – Financial Results
- Ahsay Backup Software Development Company Limited (8290.HK) Income Statement Analysis – Financial Results
- Beijing Vastdata Technology Co., Ltd. (603138.SS) Income Statement Analysis – Financial Results
- Imperial Mining Group Ltd. (IMPNF) Income Statement Analysis – Financial Results
Morepen Laboratories Limited (MOREPENLAB.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.morepen.com
About Morepen Laboratories Limited
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-gout, anti-depressant, and anti-malarial drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides fever X for fever; Pain X for pain; Fiber-X, a sat isabgol; Acidity X for acidity; Burnol, first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.02B | 14.14B | 15.42B | 11.75B | 8.40B | 7.56B | 5.98B | 5.86B | 4.85B | 4.01B | 3.67B | 3.26B | 2.89B | 2.28B | 2.12B | 1.85B | 1.48B | 1.71B |
| Cost of Revenue | 10.84B | 9.70B | 10.61B | 7.87B | 5.62B | 4.99B | 3.70B | 3.67B | 3.08B | 2.46B | 2.15B | 1.99B | 1.83B | 1.48B | 1.82B | 1.61B | 1.26B | 1.34B |
| Gross Profit | 6.18B | 4.44B | 4.81B | 3.89B | 2.78B | 2.57B | 2.28B | 2.19B | 1.77B | 1.55B | 1.52B | 1.27B | 1.06B | 799.80M | 303.93M | 241.79M | 221.88M | 371.33M |
| Gross Profit Ratio | 36.33% | 31.37% | 31.18% | 33.06% | 33.07% | 34.03% | 38.15% | 37.42% | 36.43% | 38.72% | 41.35% | 38.89% | 36.61% | 35.03% | 14.32% | 13.04% | 15.02% | 21.74% |
| Research & Development | 51.98M | 30.69M | 30.08M | 56.46M | 25.47M | 9.59M | 5.04M | 4.14M | 4.65M | 3.15M | 3.80M | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 835.68M | 141.62M | 141.85M | 121.71M | 145.53M | 152.91M | 95.44M | 29.51M | 47.90M | 0.00 | 31.20M | 23.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.10B | 661.73M | 535.80M | 496.57M | 401.10M | 327.32M | 300.37M | 257.89M | 234.53M | 0.00 | 195.50M | 204.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.94B | 803.35M | 677.65M | 618.27M | 546.63M | 480.23M | 395.81M | 287.40M | 282.43M | 516.85M | 807.30M | 738.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 44.76M | 89.77M | 99.35M | 52.87M | 28.50M | 36.02M | 36.12M | -13.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.66M | 20.11M | 100.36M | 59.93M |
| Operating Expenses | 1.99B | 3.92B | 3.72B | 3.00B | 2.46B | 2.30B | 1.98B | 1.92B | 1.49B | 1.45B | 1.48B | 1.39B | 1.35B | 1.22B | 669.27M | 715.10M | 799.16M | 794.60M |
| Cost & Expenses | 12.85B | 13.62B | 14.33B | 10.87B | 8.08B | 7.29B | 5.67B | 5.59B | 4.58B | 3.90B | 3.64B | 3.38B | 3.18B | 2.71B | 2.49B | 2.33B | 2.05B | 2.13B |
| Interest Income | 25.04M | 16.57M | 13.30M | 21.34M | 41.96M | 8.22M | 1.21M | 1.03M | 1.84M | 5.80M | 10.50M | 1.30M | 1.00M | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 37.10M | 19.81M | 24.26M | 12.99M | 14.95M | 16.14M | 38.70M | 70.74M | 105.04M | 86.58M | 99.20M | 116.30M | 79.60M | 62.70M | 35.66M | 20.11M | 100.36M | 59.93M |
| Depreciation & Amortization | 334.70M | 279.30M | 276.43M | 302.83M | 369.06M | 399.03M | 343.22M | 339.04M | 351.96M | 386.67M | 458.40M | 458.00M | 480.60M | 481.60M | 480.21M | 521.38M | 567.59M | 597.83M |
| EBITDA | 1.73B | 856.67M | 1.57B | 1.28B | 779.98M | 711.90M | 684.50M | 650.95M | 625.80M | 496.04M | 530.20M | 369.10M | 324.50M | 68.10M | 453.45M | 125.44M | 119.35M | -672.93M |
| EBITDA Ratio | 10.14% | 6.06% | 10.17% | 11.07% | 9.23% | 9.35% | 11.37% | 11.02% | 12.94% | 12.38% | 13.66% | 10.38% | 7.05% | 2.98% | 5.41% | 2.59% | -0.65% | 10.22% |
| Operating Income | 4.17B | 484.61M | 1.26B | 924.27M | 194.80M | 166.79M | 226.32M | 196.76M | 100.53M | 109.37M | 42.80M | -119.80M | -276.60M | -413.50M | -365.33M | -473.31M | -577.25M | -423.28M |
| Operating Income Ratio | 24.52% | 3.43% | 8.14% | 7.86% | 2.32% | 2.21% | 3.79% | 3.36% | 2.07% | 2.73% | 1.17% | -3.68% | -9.56% | -18.11% | -17.22% | -25.52% | -39.06% | -24.78% |
| Total Other Income/Expenses | -2.82B | -2.23B | -1.93B | 1.64B | 74.99M | 15.62M | -6.35M | -38.45M | -1.08B | -80.78M | -603.30M | -56.80M | 40.90M | -52.30M | 302.92M | 60.32M | 31.00M | -907.41M |
| Income Before Tax | 1.35B | 557.55M | 1.27B | 985.12M | 391.08M | 291.77M | 297.71M | 236.30M | 126.64M | 22.79M | -27.40M | -205.30M | -235.70M | -476.20M | -62.42M | -412.99M | -546.25M | -1.33B |
| Income Before Tax Ratio | 7.96% | 3.94% | 8.22% | 8.38% | 4.66% | 3.86% | 4.98% | 4.03% | 2.61% | 0.57% | -0.75% | -6.30% | -8.15% | -20.86% | -2.94% | -22.27% | -36.97% | -77.91% |
| Income Tax Expense | 387.95M | 170.80M | 250.21M | 14.22M | 55.29M | 3.36M | 110.67M | 109.20M | -1.35M | 1.37M | 100.00K | 50.00K | 600.00K | -6.90M | 268.00K | 6.30M | 2.38M | 255.89M |
| Net Income | 961.60M | 386.75M | 1.02B | 970.86M | 335.79M | 288.49M | 295.91M | 236.35M | 128.00M | 21.40M | -27.70M | -205.20M | -236.50M | -469.30M | -62.17M | -417.58M | -548.64M | -1.58B |
| Net Income Ratio | 5.65% | 2.74% | 6.60% | 8.26% | 4.00% | 3.81% | 4.95% | 4.03% | 2.64% | 0.53% | -0.76% | -6.30% | -8.17% | -20.56% | -2.93% | -22.51% | -37.13% | -92.78% |
| EPS | 1.88 | 0.77 | 2.26 | 2.16 | 0.75 | 0.64 | 0.66 | 0.53 | 0.28 | 0.04 | -0.06 | -0.46 | -0.53 | -1.04 | -0.15 | -1.17 | -2.16 | -7.51 |
| EPS Diluted | 1.88 | 0.77 | 1.96 | 2.15 | 0.75 | 0.64 | 0.66 | 0.53 | 0.28 | 0.04 | -0.06 | -0.46 | -0.53 | -1.04 | -0.15 | -1.17 | -2.16 | -7.51 |
| Weighted Avg Shares Out | 511.49M | 502.21M | 449.98M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 416.12M | 357.34M | 253.59M | 211.04M |
| Weighted Avg Shares Out (Dil) | 511.17M | 502.21M | 519.83M | 451.07M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 416.12M | 357.34M | 253.59M | 211.04M |
Source: https://incomestatements.info
Category: Stock Reports